胰高血糖素样肽-1(GLP-1)是小肠L细胞分泌的肠促胰岛素样多肽。大量研究表明GLP-1受体激动剂(RAs)可产生葡萄糖依赖性胰岛素分泌,抑制胰高血糖素的分泌,并降低食欲等多效性作用,在过去的10年间已经作为一类新的降糖药物被应用于临床治疗中,并认为对心血管产生积极影响。大多数临床研究均将GLP-1RAs的心血管作用...
To better understand cardiovascular responses to GLP-1 RAs, and the potential role of health behaviors in influencing these responses, we leveraged wearable technology and causal inference analysis. We tracked RHR, heart rate variability (HRV), physical activity, and sleep in 66 individuals (42卤9...
Serious allergic reactions:Serious allergic reactions to GLP-1 RAs is rare. Symptoms of serious allergic reactions, include swelling of the face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat. ...
Thus, no evidence currently indicates that patients with HFrEF benefit from the administration of GLP-1RAs, but rather, the increased arrhythmias and death are concerning. One factor that may have contributed to such a result in patients with HFrEF is the increased heart rate caused by GLP-1...
material would precipitate a large number of negative outcomes, but our data suggests when you carefully case match the controls, the rate is actually very, very low,” Kuo said, asserting that although GLP-1 RAs increases the risk of residual gastric content, the overall medical risk is low...
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have also emerged as a potential therapy. While the LIVE and FIGHT trials explored their effects on heart failure with reduced ejection fraction (HFrEF), the STEP-HFpEF trial demonstrated that GLP-1RAs improve HFpEF outcomes by reducing ...
In terms of effectiveness, the efficacy of semaglutide in controlling glycated hemoglobin (HBA1C), HBA1C < 7% qualification rate, fasting blood glucose (FPG), and lowering weight have obvious advantages compared to other GLP-1RAs. For safety aspect, the risk of semaglutide causing some ...
Interestingly, GLP-1 RAs can also reduce major adverse cardiovascular events (MACEs), such as cardiovascular death, heart failure (HF), myocardial infarction, and stroke [7]. Recent advances underscore the potential of GLP-1 RAs not only as hypoglycemic agents but also for their therapeutic ...
Blood glucose lowering effect of GLP-1RAs As previously noted, DPP-4 rapidly cleaves and inactivates GLP-1, resulting in its very short half-life (2–3 min). While DPP-4 expression is significantly increased in patients with obesity and T2DM, the incretin effect is markedly impaired. Early...
Since sodium/glucose cotransporter-2 (SGLT-2) inhibitor treatment reduces CV events as well (with the effect mainly driven by a reduction in heart failure complications), the individual risk of ischemic or heart failure complications should guide the choice of treatment. GLP-1 RAs may also help...